<DOC>
	<DOCNO>NCT01743118</DOCNO>
	<brief_summary>The current important topical treatment psoriasis vitamin D3 analogues and/or corticosteroid . The possibility another effective treatment psoriasis could base immunosuppressive efficacy selective blocker lymphocyte potassium channel . The aim clinical trial evaluate safety , tolerability anti-psoriatic efficacy topical SPS4251 formulation comparison placebo market topical Vitamin-D analogue ointment psoriasis plaque test .</brief_summary>
	<brief_title>Antipsoriatic Effect Topical Formulation Treatment Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>men age 18 year old subject mild moderate psoriasis vulgaris chronic stable phase subject three stable plaque area sufficient five treatment field Plaques treat comparable thickness Echo Lucent Band least 200 µm Subjects guttate psoriasis , punctate psoriasis , erythrodermic psoriasis , psoriatic arthropathy pustular psoriasis Local treatment antipsoriatics 4 week precede and/or trial , topical antipsoriatic treatment plaque treat trial 8 week first treatment and/or trial Systemic treatment antipsoriatics e.g . corticosteroid , cytostatics , retinoids three month first treatment trial ; Treatment systemic medication medication act locally might counter influenced trial aim Contraindications accord summary product characteristic Daivonex® Ointment ; UVtherapy within four week first treatment trial Symptoms clinically significant illness may influence outcome trial four week baseline visit trial Any history cardiovascular disease Any evidence ECG abnormality screen ECG Close affiliation Investigator ( e.g . close relative ) person work bioskin GmbH subject employee Sponsor ; Subject institutionalize legal regulatory order .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>